EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Population Pharmacokinetics and Pharmacodynamics of Sotalol Following Expedited Intravenous Loading in Patients With Atrial Arrhythmias

Venkata K Yellepeddi iD, Mohamed Ismail, T Jared Bunch, Thomas F Deering, Richard Holubkov, Robert Kennedy, Suneet Mittal, Marco Perez, Jonathan P Piccini, Parash Pokharel, Salvatore Savona iD, Nishant Verma und 2 weitere

CPT: Pharmacometrics & Systems Pharmacology · 2025

DOI: 10.1002/psp4.13302 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Venkata K Yellepeddi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Pediatrics, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Sotalol, Anti-Arrhythmia Agents, Atrial Fibrillation, Atrial Flutter. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sotalol, a class III antiarrhythmic agent, is used to maintain sinus rhythm in patients with atrial fibrillation or atrial flutter (AFIB/AFL). Despite its efficacy, sotalol's use is limited by its potential to cause life‐threatening ventricular arrhythmias due to QT interval prolongation. Traditionally, sotalol administration required hospitalization to monitor these risks. The FDA approval of intravenous (IV) sotalol for loading before oral maintenance aims to reduce hospitalization duration by facilitating an expedited loading dose, transitioning to oral maintenance therapy. This study evaluates the population pharmacokinetics (PK) and pharmacodynamics (PD) of sotalol using data from the Prospective Evaluation Analysis and Kinetics of IV Sotalol (PEAKS) Registry, which includes patients with atrial arrhythmias undergoing IV sotalol loading. A nonlinear mixed‐effect modeling approach was used to describe sotalol PK, considering covariates such as age, weight, sex, and renal function. The study also examined the correlation between sotalol plasma concentrations and corrected QT interval (QTc) prolongation. Sotalol PK after IV loading and two oral maintenance doses was adequately described by a two‐compartment model with first‐order elimination in patients with atrial arrhythmias. Weight and creatinine clearance (CrCl) were identified as covariates with significant influence on sotalol PK. A linear regression model adequately described the relationship between QTc and plasma sotalol levels ( R 2 = 0.27). The Monte Carlo simulations showed that the IV loading doses recommended in the prescribing information did not result in significant prolongation of QTc. The data from this study supports the current dosing recommendations of IV sotalol in patients with AFIB/AFL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SotalolAnti-Arrhythmia AgentsAtrial FibrillationAtrial FlutterHumansFemaleMaleAgedMiddle AgedProspective StudiesModels, BiologicalAdministration, IntravenousAdultAged, 80 and overAdministration, Oral

Stichwörter der Autor:innen

PK/PD modelingQT prolongationatrial fibrillationintravenous Sotalolpharmacodynamicspopulation pharmacokinetics

Substanzen

SotalolAnti-Arrhythmia Agents

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Department of Pediatrics, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA.
  • Department of Molecular Pharmaceutics, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA.
  • Quantitative Pharmacology, Enhanced Pharmacodynamics LLC, New York, New York, USA.
  • Division of Cardiovascular Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA.
  • Piedmont Healthcare, Atlanta, Georgia, USA.
  • Pediatric Critical Care, Department of Pediatrics, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA.

ORCID-Profile: Venkata K Yellepeddi, Salvatore Savona

Zitieren

APA

Yellepeddi, V. K., Ismail, M., Bunch, T. J., Deering, T. F., Holubkov, R., Kennedy, R., Mittal, S., Perez, M., Piccini, J. P., Pokharel, P., Savona, S., Verma, N., Steinberg, B., & Watt, K. (2025). Population Pharmacokinetics and Pharmacodynamics of Sotalol Following Expedited Intravenous Loading in Patients With Atrial Arrhythmias. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13302

Vancouver

Yellepeddi VK, Ismail M, Bunch TJ, Deering TF, Holubkov R, Kennedy R, et al. Population Pharmacokinetics and Pharmacodynamics of Sotalol Following Expedited Intravenous Loading in Patients With Atrial Arrhythmias. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.13302

BibTeX
@article{Yellepeddi2025,
  author = {Yellepeddi, Venkata K and Ismail, Mohamed and Bunch, T Jared and Deering, Thomas F and Holubkov, Richard and Kennedy, Robert and Mittal, Suneet and Perez, Marco and Piccini, Jonathan P and Pokharel, Parash and Savona, Salvatore and Verma, Nishant and Steinberg, Benjamin and Watt, Kevin},
  title = {Population Pharmacokinetics and Pharmacodynamics of Sotalol Following Expedited Intravenous Loading in Patients With Atrial Arrhythmias},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2025},
  doi = {10.1002/psp4.13302}
}
Kostenlos starten →